Hormones 2016

Ethinylestradiol
• Weight change,
• additive insulin resistance in
diabetics (Abramovitz, 2016).
Skin
• Rash,
• acne,
• erythema multiforme 60 ,
• melasma,
• hirsutism (Abramovitz, 2016).
Other
• Breast tenderness,
• breast enlargement,
• anaphylaxis,
• haemolytic-uremic syndrome
(Abramovitz, 2016).
• nausea and
• vomiting, and
• withdrawal bleeding may
occur in females (drugbank,
2013c).
Cautions
thromboem-
Cardiovascular disease (sodium retention with oedema,
bolism), hepatic impairment (jaundice) (BNF, 2016a).
Interactions
Abciximab - ethinylestradiol may ↓ the anticoagulant activities of Abciximab.
Acenocoumarol - ethinylestradiol may ↓ the anticoagulant activities of
Acenocoumarol.
Acetohexamide - The therapeutic efficacy of Acetohexamide can be ↓ when
used in combination with ethinylestradiol.
Alogliptin - The therapeutic efficacy of Alogliptin can be ↓ when used in
combination with ethinylestradiol.
Anthrax immune globulin - ethinylestradiol may ↑ the thrombogenic
activities of Anthrax immune globulin.
Batimastat - The serum concentration of ethinylestradiol can be ↓ when it
is combined with Batimastat.
Bexarotene - The serum concentration of ethinylestradiol can be ↓ when it
is combined with Bexarotene.
60 An acute eruption of macules, papules, or subdermal vesicles presenting a multiform
appearance, the characteristic lesion being the target or iris form of lesion over the dorsal
aspect of the hands and forearms; its origin may be from drug sensitivity, and the eruption,
although usually self limited, may be recurrent or may run a severe course, sometimes with
fatal termination (Eaton, 2014)
210
Version 2016.3576– – Document LATEXed – 1st May 2016
[git] • Branch: 1.5 @ 26b5e6d • Release: 1.5 (2016-05-01)